- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02956525
Phase I Study to Evaluate the Safety of Dexibuprofen 200mg Under Fasting and Fed Conditions
Phase I Clinical Study, Open-label, Randomized, Parallel to Evaluate the Safety of the 200 mg Dexibuprofen Following Single and Multiple Dose Oral Administration in Healthy Participants of Both Sexes Under Fasting and Fed Conditions.
Study Overview
Detailed Description
A single oral dose of test medicine will be administered to participants in a practical period with the aid of 200 mL of water at room temperature. During administration, participants should stay in seated position. Participants will be confined at least 12 hours prior to administration and will remain for about 24 hours after the same, totaling about 36 hours of confinement.
After 36 hours of confinement the participantes will proceed to the multi-dose use phase for seven days in fed conditions.
To assess safety, an evaluation of the vital signs, laboratory tests and health status of the participants will be carried out throughout the study.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
São Paulo
-
Valinhos, São Paulo, Brazil, 13271-130
- Azidus laboratories Ltd.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participant able to understand and sign the informed consent of the study;
- Healthy research participant, of both sexes, aged between 18 and 50 years, with BMI between 18.50 and 29.99 kg / m2;
- Participant considered healthy by evaluating the medical history, vital signs and general clinical examination;
- The results of clinical laboratory tests (biochemistry, hematology, serology, urinalysis and ECG certified by cardiologists) within the normal range established by the laboratory or changes that are considered not clinically significant by study physician.
Exclusion Criteria:
- History of any major surgery in the last three months;
- History present or previous history of any cardiac event, gastrointestinal, respiratory, hepatic, renal, endocrine, neurological, metabolic, psychiatric, hematologic, considered by the investigator as clinically significant and can endanger the participant's health;
- History of chronic alcohol abuse, drugs, drugs and / or smoking in the last 6 months;
- Known hypersensitivity to dexibuprofen, ibuprofen or its related (other nonsteroidal anti-inflammatory drugs) as well as components present in the formulation;
- History of use of drugs that potentially interfere with the kinetics / dynamics dexibuprofen or any other medication considered clinically significant by the investigator with time less than 7 times of drug half-life preceding the period of inclusion;
- Regular consumption of grapefruit and / or their derivatives;
- Pregnant women and nursing mothers;
- Donation or loss of 450 ml or more of blood within 3 months before the study and / or hospitalization for any reason, up to 4 weeks before the beginning of it.
- Participation in any clinical trial in the last 12 months preceding the start of the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Dexibuprofen 200 mg - Fed
Fed condition
|
Dexibuprofen 200 mg
|
EXPERIMENTAL: Dexibuprofen 200 mg - Fasting
Fasting condition
|
Dexibuprofen 200 mg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To assess the safety of the drug through the incidence and classification of adverse events following single and multiple dose administration.
Time Frame: 40 days
|
Adverse events both recorded in the single-dose and multiple-dose
|
40 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate the pharmacokinetics of the drug dexibuprofen at 200 mg concentration after single dose oral administration under fasting and fed conditions.
Time Frame: 36 hours
|
Evaluation of pharmacokinetic parameters: Tmax, Cmax, AUC, DV, Kel, CL and T1/2.
|
36 hours
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- DEXAPS0716OR-LD
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers
-
AstraZenecaCompletedHealthy Elderly Volunteers | Healthy Young VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
University Hospital, Clermont-FerrandUnite de Nutrition Humaine UMR 1019- INRAE; Unite MetaGenoPolis INRAE; France...CompletedHealthy Volunteers | Frail VolunteersFrance
-
Galera Therapeutics, Inc.CelerionCompletedHealthy | Healthy VolunteersUnited States
-
Newcastle UniversityCompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy VolunteersUnited Kingdom
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
PMV Pharmaceuticals, IncRecruitingHealthy VolunteersUnited States
Clinical Trials on Dexibuprofen
-
Apsen Farmaceutica S.A.CompletedHealthy VolunteersBrazil
-
Gebro Pharma GmbHCompletedOsteoarthritis of the Hip or KneeAustria
-
Inje UniversityCompletedFever | Respiratory Tract InfectionKorea, Republic of
-
University of Southern DenmarkOdense University Hospital; Region Syddanmark; Association of Danish Physiotherapists and other collaboratorsCompleted